Trial Profile
A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of Subcutaneously Administered Peginesatide in Chronic Kidney Disease Patients Not on Dialysis and Not on Erythropoiesis Stimulating Agent (ESA) Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Peginesatide (Primary) ; Peginesatide (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Affymax
- 26 May 2014 New trial record